Zepbound and Wegovy Are Coming to Medicare -- How the $50 Copay Will Impact Retirement Budgets
July is bringing a big shift for millions of Americans on Medicare – they will now gain access to obesity medications through Medicare’s new Bridge demonstration program. Eligible beneficiaries can now access GLP-1 weight-loss drugs for a monthly copay of about $50.
Included in this change are the widely used treatments from Eli Lilly's Foundayo and Zepbound, and Novo Nordisk's Wegovy that have reshaped obesity care but have remained out of reach for many seniors due to their exorbitant out-of-pocket costs.
Read Next: Mark Cuban Says Medicaid Should Be Simplified: 3 Ways His Plan Would Affect Your Premiums
For You: 9 Unusual Ways To Make Extra Money (That Actually Work)
This policy change marks a major expansion of Medicare coverage for obesity treatment. However, awareness is extremely low; a survey cited by CNBC found that about 82% of older Americans don’t know the program is launching, meaning that most eligible patients may not even realize the benefit exists.
How This Can Change Retirement Budgets
For retirees, this could be a gamechanger. GLP-1 drugs cost hundreds of dollars per month without insurance coverage (sometimes well past $1,000). The new $50 copay significantly lowers that barrier for eligible Medicare beneficiaries. That change can massively impact retirement cash flow for GLP-1 users.
Healthcare is already one of the biggest (and most unpredictable) expenses in retirement. Even a few hundred dollars in monthly savings can free up room in a fixed-income budget for essentials like housing, utilities or groceries.
There’s also a longer-term impact as well. If these medications reduce obesity-related complications over time, some retirees could also see lower spending on weight-related health conditions like cardiovascular disease or sleep apnea. Such changes could radically revise a retired senior’s overall healthcare budget.
How Seniors Can Access It
Public awareness of this crucial rollout has been limited, thanks to the Centers for Medicare & Medicaid Services (CMS) focusing its outreach mostly on healthcare providers and pharmacists rather than mass public advertising. A slower public info ramp-up helps to prevent bottlenecks and limited supplies at launch time.
Now that you know about it, however, it’s time to act. It’s important to know that this Medicare benefit is not automatic.
To use it, Medicare beneficiaries must have a BMI of 27 or higher and a comorbidity such as being pre-diabetic. They must also enroll in a Medicare prescription drug plan called Part D.
Also important to note is that some patients will be excluded, including those already receiving GLP-1 coverage through Part D or have a condition already covered under Medicare, such as diabetes or sleep apnea.
Another crucial detail: the Bridge program is administered directly by CMS rather than private insurers. This reduces the role of insurance companies in educating members, and it places more responsibility on providers, pharmacies and you, the patient. In addition, it is only approved to run through Dec. 31, 2027.
The Bottom Line
This major expansion of obesity drug access for Medicare beneficiaries carries with it a potential long-lasting impact for retirement healthcare spending. A $50 copay not only eases short-term pressures upon a retiree’s budget, but it can also lessen long-term healthcare costs by improving overall retiree health.
Summer spending adds up fast. Enter MoneyLion's Summer Break Giveaway for a chance to win $500— and give your budget a break. (No pur. nec. Ends 7/4/26. See Official Rules at mlion.info/summerbreakofficialrules)
This article was provided by MoneyLion.com for informational purposes only and should not be construed as financial, legal or tax advice.
More From MoneyLion: